|Articles|May 16, 2019
Road Ahead Still Difficult for Biosimilar Producers in US
Advertisement
The FDA has finalized its guidance on interchangeable biosimilars, but the new specifications will still make it a difficult for biosimilar producers looking to make headway in the United States. GlobalData’s Senior Immunology Pharma Analyst, Rose Joachim, weighs in.
See what she has to say
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Outlines New Superiority Standard for Future CAR-T Approvals
2
2025 Veeva R&D and Quality Summit: Advancing Site Efficiency and Collaboration in the Next Era of Clinical Trials
3
ACT Brief: New CAR-T Trial Requirements, Pfizer Advances Oral GLP-1 Strategy, and Kisqali Shows Durable Long-Term Control
4
ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
